Methods of administering amantadine

A method of achieving at least one result selected from the group consisting of (A) increasing ON time without dyskinesia, (B) reducing ON time with dyskinesia, (C) reducing ON time with troublesome dyskinesia, (D) increasing ON time without troublesome dyskinesia, (E) reducing OFF time, and (F) improving CGI in a patient with Parkinson's disease (PD), comprising administering to said patient once daily a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof, and at least one release modifying excipient.

A method improving CGI in a patient with a CNS disorder, comprising administering to said patient once daily a composition comprising 260 to 420 mg amantadine, or a pharmaceutically acceptable salt thereof, and at least one release modifying excipient.

A method comprising administering once daily 260 to 340 mg dose of amantadine, or a pharmaceutically acceptable salt thereof, to a patient in need thereof without increasing the frequency or severity of at least one adverse event selected from the group consisting of insomnia and sleep disturbance.

A method of administering once daily a dosage form comprising a therapeutically effective amount of a drug selected from the group consisting of amantadine and a pharmaceutically acceptable salt thereof, and at least one release modifying excipient to a patient in need thereof, wherein said method comprises administering to said patient a reduced amount of the drug once daily for a period of at least one week immediately preceding the once daily administration of the dosage form comprising a therapeutically effective amount of the drug.